2024
Mechanistically based blood proteomic markers in the TGF-β pathway stratify risk of hepatocellular cancer in patients with cirrhosis.
Xiang X, Bhowmick K, Shetty K, Ohshiro K, Yang X, Wong L, Yu H, Latham P, Satapathy S, Brennan C, Dima R, Chambwe N, Sharifova G, Cacaj F, John S, Crawford J, Huang H, Dasarathy S, Krainer A, He A, Amdur R, Mishra L. Mechanistically based blood proteomic markers in the TGF-β pathway stratify risk of hepatocellular cancer in patients with cirrhosis. Genes & Cancer 2024, 15: 1-14. PMID: 38323119, PMCID: PMC10843195, DOI: 10.18632/genesandcancer.234.Peer-Reviewed Original ResearchHepatocellular carcinomaPyruvate kinase M2TGF-bPresence of hepatocellular carcinomaEarly detection of HCCRisk of hepatocellular cancerDetection of hepatocellular carcinomaAdvanced incurable stageRisk-stratifying biomarkersTGF-B pathwayAssociated with hepatocellular carcinomaProteomic markersEarly detectionBiologically relevant markersIncurable stageBlood-based biomarkersHepatocellular cancerRisk stratificationStratify riskNon-HCCClinical variablesBlood levelsLiver diseaseAnimal modelsBiological role
1995
Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy.
Yu H, Diamandis E, Prestigiacomo A, Stamey T. Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clinical Chemistry 1995, 41: 430-434. PMID: 7533672, DOI: 10.1093/clinchem/41.3.430.Peer-Reviewed Original ResearchConceptsTumor-doubling timeProstate-specific antigenProstate cancer relapseRelapse-free periodRadical prostatectomyPSA assaysCancer relapseUltrasensitive prostate specific antigenProstate cancer patientsUltrasensitive assayExponential tumor growthPSA changeCancer patientsPatientsProstatectomyTumor growthEarly detectionRelapseAntigenAssaysBasis of criteriaDaysCystoprostatectomyPostsurgerySurgery